About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 546318, 8 pages
http://dx.doi.org/10.1155/2013/546318
Review Article

The Role of Epidermal Growth Factor Receptor in Cancer Metastasis and Microenvironment

1Department of Gastroenterological Surgery, Fukuoka University School of Medicine, Nanakuma 7-45-1, Jonan-ku, Fukuoka 814-0180, Japan
2Department of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8521, Japan

Received 3 May 2013; Accepted 25 June 2013

Academic Editor: Davide Vigetti

Copyright © 2013 Takamitsu Sasaki et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. Normanno, A. de Luca, C. Bianco et al., “Epidermal growth factor receptor (EGFR) signaling in cancer,” Gene, vol. 366, no. 1, pp. 2–16, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Carpenter and S. Cohen, “Epidermal growth factor,” The Journal of Biological Chemistry, vol. 265, no. 14, pp. 7709–7712, 1990. View at Scopus
  3. I. Alroy and Y. Yarden, “The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions,” FEBS Letters, vol. 410, no. 1, pp. 83–86, 1997. View at Publisher · View at Google Scholar · View at Scopus
  4. N. E. Hynes and H. A. Lane, “ERBB receptors and cancer: the complexity of targeted inhibitors,” Nature Reviews Cancer, vol. 5, no. 5, pp. 341–354, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Mendelsohn and J. Baselga, “The EGF receptor family as targets for cancer therapy,” Oncogene, vol. 19, no. 56, pp. 6550–6565, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. A. J. Wong, J. M. Ruppert, S. H. Bigner et al., “Structural alterations of the epidermal growth factor receptor gene in human gliomas,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 7, pp. 2965–2969, 1992. View at Scopus
  7. Y. Umekita, Y. Ohi, Y. Sagara, and H. Yoshida, “Co-expression of epidermal growth factor receptor and transforming growth factor-α predicts worse prognosis in breast cancer patients,” International Journal of Cancer, vol. 89, no. 6, pp. 484–487, 2000. View at Publisher · View at Google Scholar
  8. D. L. Uhlman, P. Nguen, J. C. Manivel et al., “Epidermal growth factor receptor and transforming growth factor α expression in papillary and nonpapillary renal cell carcinoma: correlation with metastatic behavior and prognosis,” Clinical Cancer Research, vol. 1, no. 8, pp. 913–920, 1995. View at Scopus
  9. D. E. B. Swinson, G. Cox, and K. J. O'Byrne, “Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer,” The British Journal of Cancer, vol. 91, no. 7, pp. 1301–1307, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. J. R. Grandis, M. F. Melhem, W. E. Gooding et al., “Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival,” Journal of the National Cancer Institute, vol. 90, no. 11, pp. 824–832, 1998. View at Scopus
  11. K. L. Carraway III and L. C. Cantley, “A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling,” Cell, vol. 78, no. 1, pp. 5–8, 1994. View at Publisher · View at Google Scholar · View at Scopus
  12. P. van der Geer, T. Hunter, and R. A. Lindberg, “Receptor protein-tyrosine kinases and their signal transduction pathways,” Annual Review of Cell Biology, vol. 10, pp. 251–337, 1994. View at Scopus
  13. A. Ullrich, L. Coussens, J. S. Hayflick et al., “Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells,” Nature, vol. 309, no. 5967, pp. 418–425, 1984. View at Scopus
  14. G. Carpenter, L. King Jr., and S. Cohen, “Epidermal growth factor stimulates phosphorylation in membrane preparations in vitro,” Nature, vol. 276, no. 5686, pp. 409–410, 1978. View at Scopus
  15. H. Ushiro and S. Cohen, “Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes,” The Journal of Biological Chemistry, vol. 255, no. 18, pp. 8363–8365, 1980. View at Scopus
  16. L. C. Groenen, E. C. Nice, and A. W. Burgess, “Structure-function relationships for the EGF/TGF-α family of mitogens,” Growth Factors, vol. 11, no. 4, pp. 235–257, 1994. View at Scopus
  17. H. Toyoda, T. Komurasaki, D. Uchida et al., “Epiregulin. A novel epidermal growth factor with mitogenic activity for rat primary hepatocytes,” The Journal of Biological Chemistry, vol. 270, no. 13, pp. 7495–7500, 1995. View at Publisher · View at Google Scholar · View at Scopus
  18. W. S. Chen, C. S. Lazar, M. Poenie, R. Y. Tsien, G. N. Gill, and M. G. Rosenfeld, “Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor,” Nature, vol. 328, no. 6133, pp. 820–823, 1987. View at Scopus
  19. R. A. Perugini, T. P. McDade, F. J. Vittimberga Jr., and M. P. Callery, “Pancreatic cancer cell proliferation phosphatidylinositol 3-kinase dependent,” Journal of Surgical Research, vol. 90, no. 1, pp. 39–44, 2000. View at Publisher · View at Google Scholar · View at Scopus
  20. K. M. Nicholson and N. G. Anderson, “The protein kinase B/Akt signalling pathway in human malignancy,” Cellular Signalling, vol. 14, no. 5, pp. 381–395, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. W. Wang, J. L. Abbruzzese, D. B. Evans, L. Larry, K. R. Cleary, and P. J. Chiao, “The nuclear factor-κB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells,” Clinical Cancer Research, vol. 5, no. 1, pp. 119–127, 1999. View at Scopus
  22. N. Douziech, E. Calvo, J. Laine, and J. Morisset, “Activation of MAP kinases in growth responsive pancreatic cancer cells,” Cellular Signalling, vol. 11, no. 8, pp. 591–602, 1999. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Yokoi, P. H. Thaker, S. Yazici et al., “Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model,” Cancer Research, vol. 65, no. 9, pp. 3716–3725, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. R. M. Shaheen, S. A. Ahmad, W. Liu et al., “Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors,” The British Journal of Cancer, vol. 85, no. 4, pp. 584–589, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. L. B. Saltz, N. J. Meropol, P. J. Loehrer Sr., M. N. Needle, J. Kopit, and R. J. Mayer, “Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor,” Journal of Clinical Oncology, vol. 22, no. 7, pp. 1201–1208, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. D. Cunningham, Y. Humblet, S. Siena et al., “Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer,” The New England Journal of Medicine, vol. 351, no. 4, pp. 337–345, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. K. P. de Jong, R. Slellema, A. Karrenbeld et al., “Clinical relevance of transforming growth factor α, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors,” Hepatology, vol. 28, no. 4 I, pp. 971–979, 1998. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Toschi and F. Cappuzzo, “Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors,” Oncologist, vol. 12, no. 2, pp. 211–220, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. D. Veale, N. Kerr, G. J. Gibson, P. J. Kelly, and A. L. Harris, “The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival,” The British Journal of Cancer, vol. 68, no. 1, pp. 162–165, 1993. View at Scopus
  30. A. Rajput, A. P. Koterba, J. L. Kreisberg, J. M. Foster, J. K. V. Willson, and M. G. Brattain, “A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo,” Cancer Research, vol. 67, no. 2, pp. 665–673, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. M. L. Janmaat and G. Giaccone, “The epidermal growth factor receptor pathway and its inhibition as anticancer therapy,” Drugs of Today, vol. 39, pp. 61–80, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Mendelsohn, “The epidermal growth factor receptor as a target for cancer therapy,” Endocrine-Related Cancer, vol. 8, no. 1, pp. 3–9, 2001. View at Publisher · View at Google Scholar · View at Scopus
  33. R. S. Herbst, “Review of epidermal growth factor receptor biology,” International Journal of Radiation Oncology Biology Physics, vol. 59, no. 2, pp. 21–26, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. R. S. Herbst, “Review of epidermal growth factor receptor biology,” International Journal of Radiation Oncology Biology Physics, vol. 59, no. 2, pp. 21–26, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. R. Radinsky, S. Risin, D. Fan et al., “Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells,” Clinical Cancer Research, vol. 1, no. 1, pp. 19–31, 1995. View at Scopus
  36. C. Barozzi, M. Ravaioli, A. D'Errico et al., “Relevance of biologic markers in colorectal carcinoma: a comparative study of a broad panel,” Cancer, vol. 94, no. 3, pp. 647–657, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. A. W. Hemming, N. L. Davis, A. Kluftinger et al., “Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67,” Journal of Surgical Oncology, vol. 51, no. 3, pp. 147–152, 1992. View at Publisher · View at Google Scholar · View at Scopus
  38. M. B. Resnick, J. Routhier, T. Konkin, E. Sabo, and V. E. Pricolo, “Epidermal growth factor receptor, c-MET, β-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study,” Clinical Cancer Research, vol. 10, no. 9, pp. 3069–3075, 2004. View at Publisher · View at Google Scholar · View at Scopus
  39. A. L. Harris, “Hypoxia—a key regulatory factor in tumour growth,” Nature Reviews Cancer, vol. 2, no. 1, pp. 38–47, 2002. View at Scopus
  40. A. Suhardja and H. Hoffman, “Role of growth factors and their receptors in proliferation of microvascular endothelial cells,” Microscopy Research and Technique, vol. 60, no. 1, pp. 70–75, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. L. M. Ellis, W. Liu, S. A. Ahmad et al., “Overview of angiogenesis: biologic implicat ions for antiangiogenic therapy,” Seminars in Oncology, vol. 28, no. 5, supplement 16, pp. 94–104, 2001. View at Publisher · View at Google Scholar
  42. R. R. Langley and I. J. Fidler, “Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis,” Endocrine Reviews, vol. 28, no. 3, pp. 297–321, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. G. P. Gupta and J. Massagué, “Cancer metastasis: building a framework,” Cell, vol. 127, no. 4, pp. 679–695, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. I. J. Fidler, S. Yano, R. Zhang, T. Fujimaki, and C. D. Bucana, “The seed and soil hypothesis: vascularisation and brain metastases,” The Lancet Oncology, vol. 3, no. 1, pp. 53–57, 2002. View at Publisher · View at Google Scholar · View at Scopus
  45. B. Hobson and J. Denekamp, “Endothelial proliferation in tumours and normal tissues: continuous labelling studies,” The British Journal of Cancer, vol. 49, no. 4, pp. 405–413, 1984. View at Scopus
  46. A. Eberhard, S. Kahlert, V. Goede, B. Hemmerlein, K. H. Plate, and H. G. Augustin, “Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies,” Cancer Research, vol. 60, no. 5, pp. 1388–1393, 2000. View at Scopus
  47. S. Iqbal and H. Lenz, “Integration of novel agents in the treatment of colorectal cancer,” Cancer Chemotherapy and Pharmacology, vol. 54, no. 1, pp. S32–S39, 2004. View at Publisher · View at Google Scholar · View at Scopus
  48. R. R. Langley, D. Fan, R. Z. Tsan et al., “Activation of the platelet-derived growth factor-receptor enhances survival of murine bone endothelial cells,” Cancer Research, vol. 64, no. 11, pp. 3727–3730, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. S. J. Kim, H. Uehara, T. Karashima, D. L. Shepherd, J. J. Killion, and I. J. Fidler, “Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice,” Clinical Cancer Research, vol. 9, no. 3, pp. 1200–1210, 2003. View at Scopus
  50. T. Sasaki, T. Nakamura, R. B. Rebhun et al., “Modification of the primary tumor microenvironment by transforming growth factor α-epidermal growth factor receptor signaling promotes metastasis in an orthotopic colon cancer model,” The American Journal of Pathology, vol. 173, no. 1, pp. 205–216, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. N. Ferrara and T. Davis-Smyth, “The biology of vascular endothelial growth factor,” Endocrine Reviews, vol. 18, no. 1, pp. 4–25, 1997. View at Publisher · View at Google Scholar · View at Scopus
  52. H. F. Dvorak, L. F. Brown, M. Detmar, and A. M. Dvorak, “Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis,” The American Journal of Pathology, vol. 146, no. 5, pp. 1029–1039, 1995. View at Scopus
  53. O. R. F. Mook, W. M. Frederiks, and C. J. F. van Noorden, “The role of gelatinases in colorectal cancer progression and metastasis,” Biochimica et Biophysica Acta, vol. 1705, no. 2, pp. 69–89, 2004. View at Publisher · View at Google Scholar · View at Scopus
  54. S. F. Schoppmann, P. Birner, J. Stöckl et al., “Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis,” The American Journal of Pathology, vol. 161, no. 3, pp. 947–956, 2002. View at Scopus
  55. K. Maruyama, J. Asai, M. Ii, T. Thorne, D. W. Losordo, and P. A. D'Amore, “Decreased macrophage number and activation lead to reduced lymphatic vessel formation and contribute to impaired diabetic wound healing,” The American Journal of Pathology, vol. 170, no. 4, pp. 1178–1191, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. T. Sasaki, Y. Kitadai, T. Nakamura et al., “Inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation on tumor-associated endothelial cells leads to treatment of orthotopic human colon cancer in nude mice,” Neoplasia, vol. 9, no. 12, pp. 1066–1077, 2007. View at Publisher · View at Google Scholar · View at Scopus
  57. N. Saito, S. Kameoka, and R. Furukawa, “Gene profile analysis of colorectal cancer cell lines by cDNA macroarray,” Oncology reports, vol. 17, no. 5, pp. 1061–1065, 2007. View at Scopus
  58. L. A. Liotta, J. Kleinerman, and G. M. Saidel, “Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation,” Cancer Research, vol. 34, no. 5, pp. 997–1004, 1974. View at Scopus
  59. J. Harder, O. Waiz, F. Otto et al., “EGFR and HER2 expression in advanced biliary tract cancer,” World Journal of Gastroenterology, vol. 15, no. 36, pp. 4511–4517, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. M. Kaufman, B. Mehrotra, S. Limaye et al., “EGFR expression in gallbladder carcinoma in North America,” International Journal of Medical Sciences, vol. 5, no. 5, pp. 285–291, 2008. View at Scopus
  61. F. Leone, G. Cavalloni, Y. Pignochino et al., “Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma,” Clinical Cancer Research, vol. 12, no. 6, pp. 1680–1685, 2006. View at Publisher · View at Google Scholar · View at Scopus
  62. A. Ooi, S. Suzuki, K. Nakazawa et al., “Gene amplification of Myc and its coamplification with ERBB2 and EGFR in gallbladder adenocarcinoma,” Anticancer Research, vol. 29, no. 1, pp. 19–26, 2009. View at Scopus
  63. Y. Pignochino, I. Sarotto, C. Peraldo-Neia et al., “Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas,” BMC Cancer, vol. 10, article 361, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. Y. Sanada, S. Osada, Y. Tokuyama et al., “Critical role of c-Met and Ki67 in progress of biliary carcinoma,” The American Surgeon, vol. 76, no. 4, pp. 372–379, 2010. View at Scopus
  65. W. S. Moon, H. S. Park, H. Lee et al., “Co-expression of cox-2, C-met and betacatenin in cells forming invasive front of gallbladder cancer,” Cancer Research and Treatment, vol. 37, no. 3, pp. 171–176, 2005. View at Publisher · View at Google Scholar
  66. K. Matsumoto, K. Date, H. Shimura, and T. Nakamura, “Acquisition of invasive phenotype in gallbladder cancer cells via mutual interaction of stromal fibroblasts and cancer cells as mediated by hepatocyte growth factor,” Japanese Journal of Cancer Research, vol. 87, no. 7, pp. 702–710, 1996. View at Scopus
  67. K. Kitamura, K. Kasuya, A. Tsuchida et al., “Immunohistochemical analysis of transforming growth factor beta in gallbladder cancer,” Oncology reports, vol. 10, no. 2, pp. 327–332, 2003. View at Scopus
  68. M. Yukawa, T. Fujimori, D. Hirayama et al., “Expression of oncogene products and growth factors in early gallbladder cancer, advanced gallbladder cancer, and chronic cholecystitis,” Human Pathology, vol. 24, no. 1, pp. 37–40, 1993. View at Publisher · View at Google Scholar · View at Scopus
  69. H. Y. Chang, M. C. Kao, T. D. Way, C. T. Ho, and E. Fu, “Diosgenin suppresses hepatocyte growth factor (HGF)-induced epithelial-mesenchymal transition by down-regulation of Mdm2 and vimentin,” Journal of Agricultural and Food Chemistry, vol. 59, no. 10, pp. 5357–5363, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. S. Barr, S. Thomson, E. Buck et al., “Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions,” Clinical and Experimental Metastasis, vol. 25, no. 6, pp. 685–693, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. D. J. McConkey, W. Choi, L. Marquis et al., “Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer,” Cancer and Metastasis Reviews, vol. 28, no. 3-4, pp. 335–344, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. A. Moustakas and C. H. Heldin, “Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression,” Cancer Science, vol. 98, no. 10, pp. 1512–1520, 2007. View at Publisher · View at Google Scholar · View at Scopus
  73. M. Y. Lee, C. Y. Chou, M. J. Tang, and M. R. Shen, “Epithelial-mesenchymal transition in cervical cancer: correlation with tumor progression, epidermal growth factor receptor overexpression, and snail up-regulation,” Clinical Cancer Research, vol. 14, no. 15, pp. 4743–4750, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. A. Hirata, S. Ogawa, T. Kometani et al., “ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase,” Cancer Research, vol. 62, no. 9, pp. 2554–2560, 2002. View at Scopus
  75. F. Ciardiello, R. Bianco, V. Damiano et al., “Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225,” Clinical Cancer Research, vol. 5, no. 4, pp. 909–916, 1999. View at Scopus
  76. C. Erlichman and D. J. Sargent, “New treatment options for colorectal cancer,” The New England Journal of Medicine, vol. 351, no. 4, pp. 391–392, 2004. View at Publisher · View at Google Scholar · View at Scopus
  77. B. Liu, M. Fang, M. Schmidt, Y. Lu, J. Mendelsohn, and Z. Fan, “Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity,” The British Journal of Cancer, vol. 82, no. 12, pp. 1991–1999, 2000. View at Scopus
  78. L. Xu, M. Hausmann, W. Dietmaier et al., “Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines,” BMC Cancer, vol. 10, article 302, 2010. View at Publisher · View at Google Scholar · View at Scopus
  79. H. Ariyama, B. Qin, E. Baba et al., “Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells,” Journal of Cellular Biochemistry, vol. 97, no. 4, pp. 724–734, 2006. View at Publisher · View at Google Scholar · View at Scopus